PTP
REGN icon

Platform Technology Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Platform Technology Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-335
Closed -$259K – 353
2025
Q4 		$259K Buy
+335
New +$228K 0.06% 213

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Platform Technology Partners's REGN Position: Q1 2026 in Review

Platform Technology Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 335 shares — an estimated $259K sold.

Platform Technology Partners first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $259K in Q4 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Platform Technology Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Platform Technology Partners sold 335 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $259K.
  • Platform Technology Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Platform Technology Partners's Regeneron Pharmaceuticals position peaked at $259K in Q4 2025.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Platform Technology Partners's 13F filing for Q1 2026, filed 27 Apr 2026.